SMARCD2: Potential Drug Target and Biomarker for Cancer (G6603)

Target Name: SMARCD2

NCBI ID: G6603

SMARCD2

Other Name(s): SMRD2_HUMAN | SMARCD2 variant 1 | Mammalian chromatin remodeling complex BRG1-associated factor 60B | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2, transcript variant 1 | SWI/SNF complex 60 kDa subunit B | Rsc6p | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 2 | PRO2451 | mammalian chromatin remodeling complex BRG1-associated factor 60B | CRACD2 | Chromatin remodeling complex BAF60B subunit | chromatin remodeling complex BAF60B subunit | Swp73-like protein | BAF60B | BRG1-associated factor 60B | 60 kDa BRG-1/Brm-associated factor subunit B | SGD2 | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d2

SMARCD2: Potential Drug Target and Biomarker for Cancer

SMARCD2 (SMRD2_HUMAN) is a protein that is expressed in human tissues and is known for its role in the development and progression of various diseases, including cancer. The SMARCD2 gene has also been identified as a potential drug target and biomarker for several diseases, including cancer.

SMARCD2 is a member of the SMAR family of proteins, which are known for their role in cell signaling and division. The SMAR family of proteins are involved in the regulation of several cellular processes, including cell growth, apoptosis, and inflammation. SMARCD2 is specifically involved in the regulation of cell division and has been shown to play a role in the development and progression of various diseases.

One of the key functions of SMARCD2 is its role in the regulation of mitosis. During mitosis, SMARCD2 helps to ensure that the number of chromosomes is accurately replicated and that the process of cell division is properly regulated. Meticulous regulation of cell division is essential for the growth and development of tissues and for the development and progression of cancer.

SMARCD2 has also been shown to play a role in the regulation of apoptosis, which is the process by which cells die when they have reached the end of their useful life. During apoptosis, SMARCD2 helps to ensure that the process is properly regulated and that the Cell death is not sudden and unpredictable. If the process of apoptosis is not properly regulated, it can lead to the development of cancer.

In addition to its role in cell division and apoptosis, SMARCD2 has also been shown to play a role in the regulation of inflammation. Chronic inflammation can contribute to the development and progression of a variety of diseases, including cancer. SMARCD2 has also been shown to help Regulate the production of pro-inflammatory cytokines, which are important drivers of inflammation.

SMARCD2 is also a potential drug target for several diseases, including cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. Chronic inflammation and other factors can contribute to the development and progression of cancer. By targeting SMARCD2, researchers may be able to develop new treatments for cancer.

One approach to targeting SMARCD2 is to use small molecules, such as drugs that bind to specific regions of the protein. Small molecules have been shown to be effective in targeting a variety of protein targets, including SMARCD2. By using small molecules to target SMARCD2, researchers may be able to inhibit its function and prevent its contribution to the development and progression of cancer.

Another approach to targeting SMARCD2 is to use antibodies, which are proteins that are specifically designed to recognize and bind to the protein. Antibodies have been shown to be effective in targeting a variety of protein targets, including SMARCD2. By using antibodies to target SMARCD2, researchers may be able to inhibit its function and prevent its contribution to the development and progression of cancer.

In addition to its potential as a drug target, SMARCD2 is also a potential biomarker for cancer. By analyzing the levels of SMARCD2 in cancer cells, researchers may be able to identify new biomarkers for cancer. This could help to improve the accuracy and effectiveness of cancer diagnostics and treatments.

Overall, SMARCD2 is a protein that has the potential to be a drug target and biomarker for cancer. Further research is needed to fully understand its role in these processes and to develop effective treatments for cancer. By targeting SMARCD2 with small molecules and antibodies, researchers may be able to inhibit its function and prevent its contribution to the development and progression of cancer.

Protein Name: SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 2

Functions: Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:22952240, PubMed:26601204). Critical regulator of myeloid differentiation, controlling granulocytopoiesis and the expression of genes involved in neutrophil granule formation (PubMed:28369036)

The "SMARCD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMARCD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets